Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Triple Negative Breast Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Cytopenia 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Cyclophosphamide 209fludarabine phosphate 184Azacitidine 159fludarabine 142Busulfan 138Tacrolimus 119Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 106Peripheral Blood Stem Cell Transplantation 98Antilymphocyte Serum 97Melphalan 90Filgrastim 87Cyclosporine 83Decitabine 82Methotrexate 79venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 47Cord Blood Stem Cell Transplantation 42Clofarabine 42thymoglobulin 41Specimen Handling 35Etoposide 35Methylprednisolone 34Sirolimus 33Injections 27Biopsy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myelodysplastic Syndromes × IDO-1 inhibitor LY3381916 × Clear all
NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
15 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡